Eli Lilly’s Olumiant is the second-in-class Jak inhibitor approved for rheumatoid arthritis (RA) in the United States. Its launch comes years...
MARKET OUTLOOK Rheumatoid arthritis (RA) is a chronic and progressive autoimmune disease that prima...
AbbVie’s JAK inhibitor, upadacitinib, is under regulatory review in both the United States and Europe for the treatment of adult moderate to...
DRG Epidemiology’s coverage of rheumatoid arthritis (RA) comprises epidemiological estimates of key p...
MARKET OUTLOOK Rheumatoid arthritis (RA) patients refractory to one or more TNF-&alp...
MARKET OUTLOOK Rheumatoid arthritis (RA) is disease characterized by chronic and progressive joint inflammation that commonly leads to permanent...
Eli Lilly’s Olumiant is the second-in-class Jak inhibitor approved for rheumatoid arthritis (RA) in the...
The mature rheumatoid arthritis (RA) market boasts ten different biologics representing several distinct drug classes, including blo...
MARKET OUTLOOK Eli Lilly’s Olumiant is the second-in-class Jak inhibitor approved for rheumatoid arthritis (
Five TNF inhibitors, five biologics with alternative mechanisms of action, and two JAK inhibitors are approved for the treatment of rheumatoid...
Rheumatoid arthritis (RA) treatment is typically initiated with cost-effective conventional DMARD
Introduction: The crowded U.S. rheumatoid arthritis (RA) market boasts nine different biologics representing five distinct drug classes, including...
Rheumatoid arthritis (RA) treatment typically begins with one or more conventional DMARDs, follow...
MARKET OUTLOOK Treatment of rheumatoid arthritis (RA) is typically initiated with cost-effective conventional
Introduction: The moderate to severe rheumatoid arthritis (RA) market is crowded; multiple targeted therapies are available, including nine ...
Introduction: The lucrative EU5 rheumatoid arthritis market is dominated by biologics, including five tumor necrosis factor (
Abstract: The mature rheumatoid arthritis (RA) market boasts ten different biologics representing several distinct drug classes, including...
Although TNF-α inhibitors and other RA biologics are generally considered efficacious and safe and...
Get content updates to your inbox
Subscribe